217 related articles for article (PubMed ID: 25546420)
1. MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide.
Morris GC; Wiggins RC; Woodhall SC; Bland JM; Taylor CR; Jespers V; Vcelar BA; Lacey CJ
PLoS One; 2014; 9(12):e116153. PubMed ID: 25546420
[TBL] [Abstract][Full Text] [Related]
2. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12.
Armbruster C; Stiegler GM; Vcelar BA; Jäger W; Köller U; Jilch R; Ammann CG; Pruenster M; Stoiber H; Katinger HW
J Antimicrob Chemother; 2004 Nov; 54(5):915-20. PubMed ID: 15456731
[TBL] [Abstract][Full Text] [Related]
3. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
Joos B; Trkola A; Kuster H; Aceto L; Fischer M; Stiegler G; Armbruster C; Vcelar B; Katinger H; Günthard HF
Antimicrob Agents Chemother; 2006 May; 50(5):1773-9. PubMed ID: 16641449
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
[TBL] [Abstract][Full Text] [Related]
5. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial.
Politch JA; Cu-Uvin S; Moench TR; Tashima KT; Marathe JG; Guthrie KM; Cabral H; Nyhuis T; Brennan M; Zeitlin L; Spiegel HML; Mayer KH; Whaley KJ; Anderson DJ
PLoS Med; 2021 Feb; 18(2):e1003495. PubMed ID: 33534791
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.
Armbruster C; Stiegler GM; Vcelar BA; Jäger W; Michael NL; Vetter N; Katinger HW
AIDS; 2002 Jan; 16(2):227-33. PubMed ID: 11807307
[TBL] [Abstract][Full Text] [Related]
8. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
[TBL] [Abstract][Full Text] [Related]
9. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.
Vcelar B; Stiegler G; Wolf HM; Muntean W; Leschnik B; Mehandru S; Markowitz M; Armbruster C; Kunert R; Eibl MM; Katinger H
AIDS; 2007 Oct; 21(16):2161-70. PubMed ID: 18090042
[TBL] [Abstract][Full Text] [Related]
10. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.
Gray ES; Meyers T; Gray G; Montefiori DC; Morris L
PLoS Med; 2006 Jul; 3(7):e255. PubMed ID: 16834457
[TBL] [Abstract][Full Text] [Related]
11. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
Mehandru S; Wrin T; Galovich J; Stiegler G; Vcelar B; Hurley A; Hogan C; Vasan S; Katinger H; Petropoulos CJ; Markowitz M
J Virol; 2004 Dec; 78(24):14039-42. PubMed ID: 15564511
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Artificial Immunogens Containing Peptide Mimotopes of HIV-1 Epitopes Recognized by Monoclonal Antibodies 2F5 and 2G12.
Shcherbakova NS; Chikaev AN; Rudometov AP; Shcherbakov DN; Il'ichev AA; Karpenko LI
Bull Exp Biol Med; 2019 Jun; 167(2):259-262. PubMed ID: 31243678
[TBL] [Abstract][Full Text] [Related]
13. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.
Wolbank S; Kunert R; Stiegler G; Katinger H
J Virol; 2003 Apr; 77(7):4095-103. PubMed ID: 12634368
[TBL] [Abstract][Full Text] [Related]
15. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.
Veselinovic M; Neff CP; Mulder LR; Akkina R
Virology; 2012 Oct; 432(2):505-10. PubMed ID: 22832125
[TBL] [Abstract][Full Text] [Related]
16. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.
Keller MJ; Carpenter CA; Lo Y; Einstein MH; Liu C; Fredricks DN; Herold BC
PLoS One; 2012; 7(10):e46901. PubMed ID: 23056520
[TBL] [Abstract][Full Text] [Related]
17. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
18. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.
Tudor D; Derrien M; Diomede L; Drillet AS; Houimel M; Moog C; Reynes JM; Lopalco L; Bomsel M
Mucosal Immunol; 2009 Sep; 2(5):412-26. PubMed ID: 19587640
[TBL] [Abstract][Full Text] [Related]
20. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1.
Matyas GR; Beck Z; Karasavvas N; Alving CR
Biochim Biophys Acta; 2009 Mar; 1788(3):660-5. PubMed ID: 19100711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
